Holen Sie sich die Stockscreener-App
20.98
2.72%
0.555
Handel nachbörslich:
21.00
0.025
+0.12%
Schlusskurs vom Vortag:
$20.42
Offen:
$20.66
24-Stunden-Volumen:
3.98M
Relative Volume:
1.01
Marktkapitalisierung:
$3.77B
Einnahmen:
$644.86M
Nettoeinkommen (Verlust:
$196.05M
KGV:
21.38
EPS:
0.9812
Netto-Cashflow:
$317.50M
1W Leistung:
-3.47%
1M Leistung:
+0.45%
6M Leistung:
-46.16%
1J Leistung:
-65.48%
1-Tages-Spanne:
$20.62
$21.35
1-Wochen-Bereich:
$20.07
$21.75
52-Wochen-Spanne:
$17.15
$76.51
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, BTSG, HQY, TEM, TXG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
20.98 | 3.67B | 644.86M | 196.05M | 317.50M | 0.9812 |
VEEV
Veeva Systems Inc
|
194.44 | 30.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
71.98 | 14.31B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
99.05 | 7.91B | 1.34B | 230.70M | 440.96M | 2.6695 |
TEM
Tempus Ai Inc
|
42.91 | 7.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
45.92 | 5.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Truist | Buy → Hold |
| 2026-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2026-02-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2026-02-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-01-08 | Hochstufung | Truist | Hold → Buy |
| 2025-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-10-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Herabstufung | Goldman | Neutral → Sell |
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Renaissance Technologies LLC Has $71.29 Million Stock Position in Doximity, Inc. $DOCS - MarketBeat
Bank of Nova Scotia Takes Position in Doximity, Inc. $DOCS - MarketBeat
Caxton Associates LLP Makes New Investment in Doximity, Inc. $DOCS - MarketBeat
TradingKey - TradingKey
Doximity Inc (DOCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Doximity Inc (DOCS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Doximity Inc (DOCS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Doximity, Inc. Revenue Breakdown – NYSE:DOCS - TradingView
Form 4 Doximity Inc For: 24 July By Investing.com - Investing.com Nigeria
DOCS|Doximity Inc|Price:20.410|Chg%:-0.040 - TradingKey
Doximity, Inc. (DOCS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Doximity Inc (DOCS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Doximity, Inc. (DOCS) Options Chain - Yahoo! Finance Canada
Doximity, Inc. (DOCS) stock price, news, quote and history - Yahoo Finance Australia
Doximity, Inc. (DOCS) Latest Stock News & Headlines - Yahoo! Finance Canada
Doximity Inc (DOCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Doximity, Inc. (DOCS) Stock Forecasts - Yahoo Finance
2 Reasons to Like DOCS (and 1 Not So Much) - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Doximity(DOCS.US) With Hold Rating, Cuts Target Price to $22 - Moomoo
Doximity Chief Accounting Officer Sitaram Siddharth disposes of 1,732 shares worth $38,150.64 - Bitget
Sparta 24 Ltd. Takes $2.94 Million Position in Doximity, Inc. $DOCS - MarketBeat
How Doximity Inc. Class A (DOCS) Affects Rotational Strategy Timing - Stock Traders Daily
A Look at Doximity Inc (DOCS) After 3.1% Decline -- GF Value $49 - GuruFocus
Zoom, AppLovin, and Doximity Shares Are Falling, What You Need To Know - Yahoo Finance
Doximity (DOCS) Declines More Than Market: Some Information for Investors - Yahoo Finance
Reasons to Retain Doximity Stock in Your Portfolio for Now - Yahoo Finance
Is AI ready to take over your prescriptions? Doctors are wary of Utah's automated refill program - AOL.com
Is Doximity (DOCS) Cheap As Its Clinical AI Tool Tops Safety Benchmark? - Sahm
AI has taken over prescription refills in Utah. Some doctors are wary - AOL.com
Medical watchdog reveals issues with recent medical student reports - AOL.com
Press Release: Doximity to Release Fiscal 2027 First Quarter Results on August 6, 2026 - Moomoo
Doximity to report fiscal Q1 2027 results on August 6 - scanx.trade
Doximity Sets Aug. 6 Webcast to Discuss Its June Quarter - Stock Titan
Doximity to Release Fiscal 2027 First Quarter Results on August 6, 2026 - Yahoo Finance
Doximity, Inc. ($DOCS) CEO 2026 Pay Revealed - Quiver Quantitative
DOCS (NYSE: DOCS) files Form 144 for 1,732-share sale - Stock Titan
Doximity (NYSE:DOCS) Attracts Renewed Market Interest - Kalkine Media
Doximity Outranks OpenEvidence, Frontier Models in Independent S - GuruFocus
11,000 Physician Experts Helped Improve Doximity's Clinical AI - Stock Titan
Doximity Outranks OpenEvidence, Frontier Models in Independent Stanford-Harvard Study of Clinical AI Safety - Mid Florida Newspapers
Form DEF 14A Doximity For: 15 July By Investing.com - Investing.com Nigeria
Doximity | DEF 14A: Definitive information statements - Moomoo
Doximity (NYSE: DOCS) sets 2026 virtual meeting, pay and auditor votes - Stock Titan
Doximity (NYSE:DOCS) Upgraded at Zacks Research - MarketBeat
Doximity, Inc. SEC Filing (Jul 15, 2026) - Stock Titan
Form 4 Doximity Inc For: 14 July By Investing.com - Investing.com Nigeria
Doximity (DOCS) director receives 9,750 RSUs as committee voids part of prior grant - Stock Titan
Equity grant: Doximity (NYSE: DOCS) gives 21,314 RSUs to director - Stock Titan
Doximity, Inc. (DOCS) Stock Analysis: Navigating a 12.66% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Doximity (DOCS) Q4 2026 earnings summary - Quartr
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.25%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):